31 recruiting. 31 Phase 2, 5 Phase 3, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 31 | Recruiting 31 |
| Phase 3 | 5 | Recruiting 5 |
| Phase 1 | 3 | Recruiting 3 |
Follow Abnormalities, Multiple: new trials by email Literature Review of Abnormalities, Multiple trials Research Report on Abnormalities, Multiple
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bempedoic Acid Therapy for Polycystic Kidney Disease Bempedoic Acid 180 MG Oral Tablet, Placebo Capsule(s) - ADPKD (Autosomal Dominant Polycystic Kidney Disease) | Phase 2 | Recruiting | Kenneth Hallows | 120 | 2026-09-01 | 2026-09-29 |
| A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD) Mivelsiran, Placebo - Down Syndrome-Associated Alzheimer's Disease (DS-AD) | Phase 2 | Recruiting | Alnylam Pharmaceuticals | 58 | 2026-08-17 | 2026-11-18 |
| Metric-Optimized Spectacle Prescriptions for Children With Down Syndrome Metric-optimized spectacles, Routine Clinical Spectacles - Refractive Error Correction, Visual Acuity | Phase 2 | Recruiting | Ohio State University | 24 | 2026-07-13 | 2026-07-20 |
| KCD (Carfilzomib/Cyclophosphamide/Dexamethasone) Regimen for the Treatment of Newly Diagnosed POEMS Syndrome CARFILZOMIB, CYCLOPHOSPHAMIDE, DEXAMETHASONE - POEMS Syndrome | Phase 2 | Recruiting | Shanghai Changzheng Hospital | 20 | 2026-06-15 | 2026-06-17 |
| Modulation of the Immune System in Down Syndrome for Improved Outcomes and Neurodevelopment - 1 Tofacitinib Oral Solution, Placebo - Down Syndrome | Phase 2 | Recruiting | University of Colorado, Denver | 92 | 2026-05-28 | 2026-09-03 |
| A Study of CSTI-500 in Patients With Prader-Willi Syndrome CSTI-500 - Prader-Willi Syndrome | Phase 2 | Recruiting | ConSynance Therapeutics | 12 | 2026-05-18 | 2026-10-21 |
| Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD) Hematopoietic stem cell transplant (HSCT) - Common Variable Immunodeficiency (CVID), Primary Immune Regulatory Disorder | Phase 2 | Recruiting | Paul Szabolcs | 25 | 2026-05-04 | 2026-05-15 |
| Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome QRX003 - Netherton Syndrome | Phase 2 / Phase 3 | Recruiting | Quoin Pharmaceuticals | 16 | 2026-03-19 | 2026-09-28 |
| CAT-VHL Exploring the Role of Carbonic Anhydrase IX as Diagnostic and Theranostic Target in Von-Hippel Lindau Disease investigating the role of CAIX as target in VHL disease and in VHL-/- tumors. - VHL - Von Hippel-Lindau Syndrome | Phase 2 | Recruiting | IRCCS Ospedale San Raffaele | 38 | 2026-02-25 | 2026-03-09 |
| Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome Abrocitinib - Atopic Dermatitis, Alopecia Areata | Phase 2 | Recruiting | Icahn School of Medicine at Mount Sinai | 56 | 2026-01-12 | 2026-10-16 |
| AEF0217 in Participants With Down Syndrome AEF0217 100 µg, AEF0217 300 µg, Placebo - Down Syndrome (Trisomy 21) | Phase 2 | Recruiting | Aelis Farma | 188 | 2025-12-22 | 2026-04-08 |
| A Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman Syndrome MVX-220 - Angelman Syndrome | Phase 1 / Phase 2 | Recruiting | MavriX Bio, LLC | 12 | 2025-10-29 | 2026-07-24 |
| Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome QRX003, 4% Lotion - Netherton Syndrome | Phase 2 / Phase 3 | Recruiting | Quoin Pharmaceuticals | 8 | 2025-10-06 | 2026-08-31 |
| BCMA/CD3 BsAb Therapy for POEMS Syndrome CM336 (BCMA/CD3 bispecific antibody) - POEMS Syndrome | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 10 | 2025-08-04 | 2026-09-29 |
| ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) ABBV-CLS-628, Placebo - Autosomal Dominant Polycystic Kidney Disease | Phase 2 | Recruiting | Calico Life Sciences LLC | 240 | 2025-06-09 | 2026-10-06 |
| Trial of JMKX003142 in Participants With Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD) JMKX003142 will be administered orally, Plcacebo - ADPKD (Autosomal Dominant Polycystic Kidney Disease) | Phase 2 | Recruiting | Jemincare | 135 | 2025-03-13 | 2025-07-03 |
| A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO) OpCT-001 - Primary Photoreceptor Disease, Retinitis Pigmentosa (RP) | Phase 1 / Phase 2 | Recruiting | BlueRock Therapeutics | 54 | 2025-03-10 | 2026-10-15 |
| Glucagon-Like Peptide-1 Receptor Agonist in ADPKD Tirzepatide, Placebo - Autosomal Dominant Polycystic Kidney, Obesity | Phase 2 | Recruiting | University of Colorado, Denver | 126 | 2025-03-06 | 2025-05-06 |
| Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders Sertraline, Placebo - Neurodevelopmental Disorders, Autism | Phase 2 | Recruiting | Holland Bloorview Kids Rehabilitation Hospital | 130 | 2024-09-16 | 2026-07-27 |
| Cornelia De Lange Syndrome: Assessing Positive Effects of Lithium Treatment Lithium Carbonate Capsule - Cornelia De Lange Syndrome | Phase 2 / Phase 3 | Recruiting | University of Milan | 34 | 2024-05-01 | 2025-01-28 |
Showing 20 of 31. Sign in to see all of them.
Down Syndrome (10) · Polycystic Kidney, Autosomal Dominant (5) · von Hippel-Lindau Disease (4) · Alzheimer Disease (3) · Netherton Syndrome (3) · Cognitive Dysfunction (2) · DiGeorge Syndrome (2) · Neuroectodermal Tumors, Primitive (2) · POEMS Syndrome (2) · Paraganglioma (2) · Pheochromocytoma (2) · 22q11 Deletion Syndrome (1) · Adenoma, Islet Cell (1) · Alopecia Areata (1) · Angelman Syndrome (1)
Congenital Abnormalities (31) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (31) · Genetic Diseases, Inborn (29) · Nervous System Diseases (21) · Chromosome Disorders (15) · Neurologic Manifestations (14) · Intellectual Disability (13) · Neurobehavioral Manifestations (13) · Ciliopathies (9) · Cardiovascular Diseases (6) · Female Urogenital Diseases (6) · Female Urogenital Diseases and Pregnancy Complications (6) · Kidney Diseases (6) · Male Urogenital Diseases (6)
Dexamethasone (2) · belzutifan (2) · 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid (1) · Asparaginase (1) · Biopsy (1) · Calcium Dobesilate (1) · Cyclophosphamide (1) · Cytarabine (1) · Gonadotropin-Releasing Hormone (1) · Hydrocortisone (1) · Leuprolide (1) · Lithium Carbonate (1) · Mercaptopurine (1) · Methotrexate (1) · N,N-dicyclohexyl-isoborneol-10-sulfonamide (1)
Quoin Pharmaceuticals (3) · National Cancer Institute (NCI) (2) · University of Colorado, Denver (2) · AC Immune SA (1) · Aelis Farma (1) · Alnylam Pharmaceuticals (1) · BlueRock Therapeutics (1) · Brigham and Women's Hospital (1) · Calico Life Sciences LLC (1) · ConSynance Therapeutics (1) · EspeRare Foundation (1) · Holland Bloorview Kids Rehabilitation Hospital (1) · IRCCS Ospedale San Raffaele (1) · Icahn School of Medicine at Mount Sinai (1) · Institute of Hematology & Blood Diseases Hospital, China (1)
United States (21) · Italy (6) · Spain (6) · United Kingdom (5) · Canada (4) · China (4) · France (4) · Australia (3) · Germany (3) · Netherlands (3) · Japan (2) · Portugal (2) · South Korea (2) · Belgium (1) · Brazil (1)
Aglaia Vignoli, Professor, MD (1) · Alexander C Conley, Ph.D. (1) · Dana Miskulin, MD (1) · Dr. Evdokia Anagnostou (1) · Dusan Bogunovic, PhD (1) · Emma Guttman, MD (1) · Haiyan He, Dr. (1) · Holm Schneider, MD (1) · Hong Zhang, Ph.D (1) · Joaquin Espinosa, PhD (1) · Kenneth R Hallows, MD, PhD, FASN (1) · Michael Rafii, MD (1) · Naris Nilubol, M.D. (1) · Nelly Pitteloud, MD (1)
PMID 41348481, PMID 41385299, PMID 35622074, PMID 36048943, PMID 41124218, PMID 41671463
2023 (1), 2025 (1), R01DK138915 (1), R01EY024590 (1), R61AR084210 (1), U10CA180886 (1)